Successful curative resection of gallbladder cancer following S‑1 chemotherapy: A case report and review of the literature

Einama,Takahiro; Uchida,Koichiro; Taniguchi,Masahiko; Ota,Yu; Watanabe,Kenji; Imai,Koji; Karasaki,Hidenori; Chiba,Atsushi; Oikawa,Kensuke; Miyokawa,Naoyuki; Furukawa,Hiroyuki

doi:10.3892/ol.2014.2565

Successful curative resection of gallbladder cancer following S‑1 chemotherapy: A case report and review of the literature

Authors:
- Takahiro Einama
- Koichiro Uchida
- Masahiko Taniguchi
- Yu Ota
- Kenji Watanabe
- Koji Imai
- Hidenori Karasaki
- Atsushi Chiba
- Kensuke Oikawa
- Naoyuki Miyokawa
- Hiroyuki Furukawa
View Affiliations

Affiliations: Division of Gastroenterological and General Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan, Digestive Disease Center, Asahikawa City Hospital, Hokkaido 070‑8610, Japan, Department of Surgical Pathology, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan
Published online on: September 26, 2014 https://doi.org/10.3892/ol.2014.2565
Pages: 2443-2447

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The symptoms of gallbladder cancer (GBC) are vague and non‑specific. Therefore, GBC is often detected at an advanced or metastatic stage. The most effective treatment for GBC is surgical resection, however the majority of GBC cases are unresectable at the time of diagnosis. Therefore, numerous GBC patients undergo chemotherapy. This study reports the case of a 60‑year‑old female with GBC who underwent successful surgical curative resection following a single dose of the chemotherapeutic agent, S‑1, twice daily for 4 weeks followed by a 14-day rest period for 36 months. S‑1 is a novel orally administered drug composed of a combination of the 5‑fluorouracil (5‑FU) prodrug, tegafur, 5‑chloro‑2,4‑dihydroxypyridine (CDHP) and oteracil potassium in a 1:0.4:1 molar concentration ratio. The focus of the present study was the candidate factors that affect the therapeutic efficacy of S‑1‑based chemotherapy. In particular, the gene expression involved in the S‑1 metabolic pathway was investigated by assessing the intratumoral dihydropyrimidine dehydrogenase (DPD), thymidylate synthase (TS) and orotate phosphoribosyltransferase gene expression. The surgical specimen exhibited high intratumoral DPD gene expression levels compared with those observed in previously reported non S‑1 responsive cases of biliary tract cancer. Due to the results obtained in the current study, we hypothesize that CDHP enhanced the antitumor efficacy of 5‑FU by inhibiting the excess DPD protein produced by the tumor.

View Figures

View References

1	Zhu AX, Hong TS, Hezel AF and Kooby DA: Current management of gallbladder carcinoma. Oncologist. 15:168–181. 2010.
2	Glimelius B, Hoffman K, Sjödén PO, et al: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 7:593–600. 1996.
3	Ishikawa T, Horimi T, Shima Y, et al: Evaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder. J Hepatobiliary Pancreat Surg. 10:233–238. 2003.
4	Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996.
5	Boku N, Yamamoto S, Fukuda H, et al: Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009.
6	Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9:215–221. 2008.
7	Ueno H, Okusaka T, Ikeda M, Takezako Y and Morizane C: Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 91:1769–1774. 2004.
8	Van Triest B, Pinedo HM, Giaccone G and Peters GJ: Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol. 2000 Apr;11(4): 385–91
9	Miyoshi Y, Uemura H, Ishiguro H, et al: Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis. 8:260–265. 2005.
10	Diasio RB and Lu Z: Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol. 12:2239–2242. 1994.
11	Kuramochi H, Hayashi K, Uchida K, et al: Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res. 12:29–33. 2006.
12	Manfredi S, Benhamiche AM, Isambert N, et al: Trends in incidence and management of gallbladder carcinoma: a population-based study in France. Cancer. 89:757–762. 2000.
13	Grobmyer SR, Lieberman MD and Daly JM: Gallbladder cancer in the twentieth century: single institution’s experience. World J Surg. 28:47–49. 2004.
14	Kitajima K, Kobayashi S, Shiba H, et al: Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene. Int J Clin Oncol. 13:545–551. 2008.
15	Bismuth H, Adam R, Lévi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 224:509–520. 1996.
16	Alberts SR, Horvath WL, Sternfeld WC, et al: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 23:9243–9249. 2005.
17	Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 8:347–353. 2001.
18	Morimoto H, Ajiki T, Takase S, et al: Resection of gallbladder cancer with hepatic metastasis after chemotherapy with gemcitabine. J Hepatobiliary Pancreat Surg. 15:655–658. 2008.
19	Takita M, Iwasaki E, Hatogai K, et al: Advanced gallbladder cancer that showed complete response to gemcitabine plus S-1 chemotherapy. Nihon Shokakibyo Gakkai Zasshi. 108:1263–1270. 2011.(in Japanese).
20	Soong R, Shah N, Salto-Tellez M, et al: Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 19:915–919. 2008.